Companies › AO GENERIUM
3 active drug programs in 3 registered trials: 1 Phase 3, 1 Phase 2, 1 Phase 1; Neurology, Ophthalmology; next expected readout Dec 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| GNR-139 Aflibercept biosimilar; VEGF-A and PlGF antagonist; binds VEGFR1 and VEGFR2 | FLT1, KDR, FLT4 | Phase 3 | nAMD | May 2028 |
| GNR-055 Iduronate-2-sulfatase (I2S) enzyme replacement therapy | – | Phase 2 | Mucopolysaccharidosis Type II | Dec 2027 |
| GNR-097 AAV9-delivered truncated dystrophin gene therapy (micro-dystrophin) | DMD | Phase 1 | Duchenne Muscular Dystrophy | Aug 2029 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05208281 | GNR-055 | Phase 2 | Mucopolysaccharidosis Type II | Neurology | Dec 2027 |
| NCT07844148 | GNR-139 | Phase 3 | nAMD | Ophthalmology | May 2028 |
| NCT07673809 | GNR-097 | Phase 1 | Duchenne Muscular Dystrophy | Neurology | Aug 2029 |
Hutchmed Merck & Co. (MSD) Takeda Chipscreen Biosciences Avalyn Pharma Mannkind Ocular Therapeutix Betta Pharmaceuticals Criterium Chia Tai Tianqing Pharmaceutical Group
NS Pharma Nippon Shinyaku Avidity Biosciences Sarepta Therapeutics Elpida Therapeutics SPC
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.